Audited Standalone Financial Results for the quarter and financial year ended March 31, 2026 and declaration of unmodified opinion on the Financial Results.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 3.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zenotech Laboratories reported revenue from operations of ₹3,956.20 lakhs for FY2026, marginally up from ₹3,897.57 lakhs in FY2025. However, the company swung to a net loss of ₹107.21 lakhs compared to a profit of ₹561.29 lakhs in the previous year—a sharp decline driven by higher tax expenses including ₹477.18 lakhs in deferred tax charges and ₹526.11 lakhs total tax expense. Q4 FY26 alone showed a loss of ₹315.08 lakhs. Exceptional items of ₹19.51 lakhs (negative) included provisions for labour code changes (₹24.48 lakhs) partially offset by EPCG scheme reversals. Cash flow from operations remained healthy at ₹1,020.48 lakhs. The statutory auditor GSKA & Co. issued an unmodified (clean) opinion.
The company swung to a net loss for FY2026 due to significant deferred tax charges, which is a major concern for shareholders despite positive operating cash flows and marginal revenue growth.